Technology
Phylloceuticals offers two complementary bioproduction formats to address many bioproduction demands
These growth formats offer advantages for different production needs
1. Vertical – Transient genetically modified tobacco bioproduction format – able to produce kgs / week within 3 weeks notice
- Ideal for providing immediate production of urgently needed vaccine antigens and antibodies (pandemic needs), eliminating the long wait period for bioproduction
2. Aquaculture - Lemna bioproduction format – stable genetically modified Lemna is ideal for lower cost, larger scale continuous production for biomolecules.
- Genetic stability of transgenes in Lemna enables consistent recombinant protein expression over years of production
- Lemna has the fastest, clonal growth of any bioproduction platform highly suitable for large scale production with simple, low-cost growth conditions.
PHYLLOCEUTICALS brings these platforms together in one offering
- Plant Made Pharmaceuticals (PMP)
- Pharmaceuticals as a Service Technology (PhAAST™)
Employing the well-developed and proven plant-made pharmaceutical (PMP) platform, biologics and vaccines can now be easily manufactured and delivered locally, regionally or globally from anywhere. Plants grow quickly and can be encouraged to produce required proteins without the capital expense of traditional big stainless steel bioreactor infrastructure.
Over the last 30 years advancements in using recombinant technologies have been used to produce therapeutic biologic molecules, i.e. antibodies, vaccines, peptides and others. The PMP sector has grown rapidly, in conjunction with the overall biologics revolution, contributing to improvement in human health in developed countries.
The 2020 pandemic has focused the world on food security and pharmaceutical security and is driving every country around the world to consider ways to manufacture and supply their citizens with needed medicines. PMP and Phylloceuticals’ PhAAST™ platform are keenly aware of this dynamic and have been assisting countries, regions and companies with ways to mitigate their supply chain issues around needed cancer, diabetes and inflammatory disease medicines with their rapid response platform.
Our response to these opportunities is to provide PHarmaceuticals As A Service Technology (PhAAST™) to customers in key geographic regions around the world.
The key features of PhAAST™ are:
- Lower cost facilities and operations
- Continuous improvements in plant-made pharmaceutical manufacturing systems
- Rapid process and product development of new pharmaceutical candidates
- Continuously optimized product vectors for an expanding product pipeline and increased production yield.
- Management and staff recruitment and training
- Automation, manufacturing data security, and AI-based process management brings the “Next-Gen”, plant-made pharmaceutical manufacturing platform to global centers.
- Global regulatory strategy support and clinical trial structure and management
- Definition of geographic regions for marketing products, with a special emphasis on bringing biologics manufacturing security to under served markets
- Assistance with obtaining capital
